Business
Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia
AOC 1001 for DM1 on track for initiation of Phase 1/2 study in 2H 2021 Meaningful pipeline advancement; moving up FSHD clinical trial initiation to 2022 and
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"AOC 1001 for DM1 on track for initiation of Phase 1/2 study in 2H 2021\n Meaningful pipeline advancement; moving up FSHD clinical trial initiation to 2022 and progressing 3 programs for DMD\n Further platform expansion beyond skeletal muscle through research collaboration with MyoKardia, a Wholly-Owned Subsidiary of Bristol Myers Squibb\n\n\nLA JOLLA, Calif., Jan. 8, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research collaboration with MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb. \n\n \n \n \n \n \n \n\n \n\"In 2021, we enter an important new phase for Avidity as AOC 1001 is expected to enter Phase 1/2 studies for the treatment of adults with myotonic dystrophy type 1, a rare, progressive muscle disease with no approved therapy,\" said Sarah Boyce, President and Chief Executive Officer. \"This milestone is the culmination of years of engineering and research laying the groundwork for the progress of our muscle franchise and future expansion of our AOC platform.\" \n2021 Pipeline Updates\nIn 2H 2021, Avidity plans to initiate a Phase 1/2 clinical study of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). AOC FSHD is a therapeutic program in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). In 2021, Avidity plans to advance the program into IND-enabling studies. In 2022, Avidity plans to submit a regulatory filing to support a clinical trial. AOC DMD is a therapeutic program in development for the treatment of Duchenne muscular dystrophy (DMD). Avidity has expanded its efforts for this indication and is now advancing three programs for DMD which target different mutations that are amenable to skipping, including Exon 44, Exon 51 and Exon 45. Avidity's lead AOC in development for DMD targets Exon 44. In 2022, Avidity plans to submit a regulatory filing to support a clinical trial. AOC Muscle Atrophy is a therapeutic program in development for the treatment of muscle atrophy (MA). During 2021, Avidity researchers will evaluate AOCs in multiple disease models of MA to identify an optimal development path. Research Collaboration with MyoKardia, a Wholly-Owned Subsidiary of ...